Govt panel recommends market authorisation for Serum’s cervical cancer vaccine
New Delhi, Jun 15: The subject expert committee (SEC) under the Drugs Controller General of India (DCGI) on Wednesday recommended granting of market authorisation to Serum Institute of India (SII) to manufacture indigenously-developed India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical…
Read More
0